JP2009512719A - Ｉａｐｂｉｒドメイン結合化合物 - Google Patents

Ｉａｐｂｉｒドメイン結合化合物 Download PDF

Info

Publication number
JP2009512719A
JP2009512719A JP2008536890A JP2008536890A JP2009512719A JP 2009512719 A JP2009512719 A JP 2009512719A JP 2008536890 A JP2008536890 A JP 2008536890A JP 2008536890 A JP2008536890 A JP 2008536890A JP 2009512719 A JP2009512719 A JP 2009512719A
Authority
JP
Japan
Prior art keywords
alkyl
compound
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008536890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512719A5 (https=
Inventor
アレイン ローレン，
キム ヒューイット，
スティーブン モリス，
パトリック ビューロー，
アレイン ブードロー，
スコット ジャービス，
ジェイムス ビー． ジェイキス，
Original Assignee
アエゲラ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエゲラ セラピューティクス インコーポレイテッド filed Critical アエゲラ セラピューティクス インコーポレイテッド
Publication of JP2009512719A publication Critical patent/JP2009512719A/ja
Publication of JP2009512719A5 publication Critical patent/JP2009512719A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008536890A 2005-10-25 2006-10-20 Ｉａｐｂｉｒドメイン結合化合物 Pending JP2009512719A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72972705P 2005-10-25 2005-10-25
US83066206P 2006-07-14 2006-07-14
PCT/CA2006/001721 WO2007048224A1 (en) 2005-10-25 2006-10-20 Iap bir domain binding compounds

Publications (2)

Publication Number Publication Date
JP2009512719A true JP2009512719A (ja) 2009-03-26
JP2009512719A5 JP2009512719A5 (https=) 2009-12-03

Family

ID=37965208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536890A Pending JP2009512719A (ja) 2005-10-25 2006-10-20 Ｉａｐｂｉｒドメイン結合化合物

Country Status (10)

Country Link
US (4) US7589118B2 (https=)
EP (1) EP1951698A4 (https=)
JP (1) JP2009512719A (https=)
KR (1) KR20080067357A (https=)
AU (1) AU2006308453B9 (https=)
BR (1) BRPI0617751A2 (https=)
CA (1) CA2564872C (https=)
IL (1) IL190936A0 (https=)
RU (1) RU2418807C2 (https=)
WO (1) WO2007048224A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520466A (ja) * 2010-02-25 2013-06-06 ノバルティス アーゲー 二量体ｉａｐ阻害剤
JP2022523882A (ja) * 2019-04-05 2022-04-26 へパジーン セラピューティクス （エイチケイ） リミテッド アポトーシスタンパク質の阻害剤の二価拮抗薬

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
JP4954983B2 (ja) * 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7807699B2 (en) * 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008134679A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US20120141496A1 (en) * 2007-12-17 2012-06-07 Aegera Therapeutics, Inc. Iap bir domain binding compounds
AU2009203971A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of IAP
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009261919A1 (en) * 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
JP2011529962A (ja) * 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8779280B2 (en) * 2009-08-18 2014-07-15 Lg Electronics Inc. Solar cell and method of manufacturing the same
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN119677743A (zh) * 2023-02-08 2025-03-21 成都先导药物开发股份有限公司 杂环化合物及其用途
KR102848239B1 (ko) * 2023-04-13 2025-08-19 성신여자대학교 연구 산학협력단 비천연 아미노산을 포함하는 htra 표적 테트라펩타이드 프로브

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20050197403A1 (en) * 2004-03-01 2005-09-08 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680077B2 (ja) 1985-02-08 1994-10-12 サントリー株式会社 プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物
US5750646A (en) 1987-09-24 1998-05-12 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
GB9016810D0 (en) 1990-07-31 1990-09-12 Wellcome Found Peptides
JPH04208299A (ja) 1990-11-30 1992-07-29 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
US5387671A (en) 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
KR100213201B1 (ko) * 1996-05-15 1999-08-02 윤종용 씨모스 트랜지스터 및 그 제조방법
US6423689B1 (en) 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
DK1100824T3 (da) 1998-06-30 2011-06-20 Helsinn Therapeutics Us Inc Forbindelser med væksthormonfrigivende egenskaber
US6110691A (en) * 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2004007529A2 (en) * 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
JP2004531731A (ja) 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US20060258581A1 (en) * 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
KR20090046973A (ko) * 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
WO2004066958A2 (en) * 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
EP1715882A4 (en) 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
CN1953744A (zh) 2004-02-05 2007-04-25 诺瓦提斯公司 Dna拓扑异构酶抑制剂和iap抑制剂的组合
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
DK2253614T3 (da) 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR100984459B1 (ko) * 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
CA2573644A1 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
US20070003535A1 (en) * 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
CA2617642A1 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7807699B2 (en) 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
NZ572531A (en) 2006-05-05 2011-09-30 Univ Michigan Bivalent smac mimetics and the uses thereof
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
AU2007325280B2 (en) 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
JP2010511057A (ja) 2006-11-28 2010-04-08 ノバルティス アーゲー 急性骨髄性白血病の処置のためのｉａｐ阻害剤の使用
BRPI0720049A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
NZ577150A (en) 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
US20100203012A1 (en) 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
CN102099035A (zh) 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节
TW201011006A (en) 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
AU2009261919A1 (en) 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US20120009141A1 (en) 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2010033531A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US20110177060A1 (en) 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
JP2006501181A (ja) * 2002-07-02 2006-01-12 ノバルティス アクチエンゲゼルシャフト Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
US20050197403A1 (en) * 2004-03-01 2005-09-08 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520466A (ja) * 2010-02-25 2013-06-06 ノバルティス アーゲー 二量体ｉａｐ阻害剤
JP2022523882A (ja) * 2019-04-05 2022-04-26 へパジーン セラピューティクス （エイチケイ） リミテッド アポトーシスタンパク質の阻害剤の二価拮抗薬
JP7455141B2 (ja) 2019-04-05 2024-03-25 へパジーン セラピューティクス （エイチケイ） リミテッド アポトーシスタンパク質の阻害剤の二価拮抗薬

Also Published As

Publication number Publication date
US20070093428A1 (en) 2007-04-26
BRPI0617751A2 (pt) 2011-08-02
CA2564872C (en) 2010-12-21
CA2564872A1 (en) 2007-04-25
AU2006308453B2 (en) 2011-07-28
WO2007048224A1 (en) 2007-05-03
IL190936A0 (en) 2009-09-22
US20080014207A1 (en) 2008-01-17
AU2006308453A8 (en) 2008-05-29
RU2008120408A (ru) 2009-12-10
AU2006308453A1 (en) 2007-05-03
US7795298B2 (en) 2010-09-14
KR20080067357A (ko) 2008-07-18
US7589118B2 (en) 2009-09-15
US8063095B2 (en) 2011-11-22
US20070093429A1 (en) 2007-04-26
RU2418807C2 (ru) 2011-05-20
US20070219140A1 (en) 2007-09-20
US7547724B2 (en) 2009-06-16
AU2006308453B9 (en) 2011-12-01
EP1951698A4 (en) 2010-04-28
EP1951698A1 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
JP5419685B2 (ja) Ｉａｐｂｉｒドメイン結合タンパク質
JP2009512719A (ja) Ｉａｐｂｉｒドメイン結合化合物
JP5419468B2 (ja) Ｉａｐのｂｉｒドメインに結合する化合物
JP4954983B2 (ja) Ｂｉｒドメイン結合化合物
US7601686B2 (en) Hepatitis C virus inhibitors
WO2009136290A1 (en) Functionalized pyrrolidines and use thereof as iap inhibitors
US7135462B2 (en) Hepatitis C virus inhibitors
CN102985439B (zh) Iap bir结构域结合化合物
WO2009155709A1 (en) Bridged secondary amines and use thereof as iap bir domain binding compounds
WO2007101347A1 (en) Bir domain binding compounds
EA012810B1 (ru) Димерные ингибиторы ингибиторов белков апоптоза (iap)
WO2010015090A1 (en) Functionalized pyrrolidines and use thereof as iap inhibitors
WO2010031171A1 (en) Iap bir domain binding compounds
US20240083846A1 (en) Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof
CA2419870A1 (en) Sh2 domain binding inhibitors
RU2446170C2 (ru) Соединения, связывающиеся с bir доменом iap
MX2008005477A (en) Iap bir domain binding compounds
RU2472780C2 (ru) Соединения, связывающие домен bir белков iap
CN103965165B (zh) 一种抑制凋亡抑制蛋白的异喹啉化合物及其制备方法与应用
CN101360728A (zh) Iap bir结构域结合化合物
HK1124852A (en) Iap bir domain binding compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101007

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120330

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120629

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120706

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20121022

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130204